GO:0019104 DNA N-glycosylase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0019104 DNA N-glycosylase activity is a molecular function that removes damaged or mismatched bases by cleaving the N-C1' glycosidic bond, leaving an apurinic/apyrimidinic (AP) site.
• This activity initiates the base excision repair (BER) pathway and is essential for genome stability.
• Key enzymes include UNG, SMUG1, MBD4, TDG, OGG1, NTHL1, NEIL1, NEIL2, NEIL3, MPG, and MUTYH, each with distinct substrate specificities [5,6,7,8].
• Defects in DNA N-glycosylases are linked to cancer predisposition, neurodegeneration, and resistance to alkylating chemotherapy [1,3].
• CRISPR knockout, point mutation, knock-in, and overexpression models enable precise dissection of DNA N-glycosylase function in disease and drug response [3,7].
• EDITGENE provides end-to-end CRISPR services to study DNA N-glycosylase activity, from model generation to library screening and bioinformatics.
Description
DNA N-glycosylase activity (GO:0019104) is a fundamental molecular function that initiates the base excision repair (BER) pathway by recognizing and removing damaged or inappropriate DNA bases. This activity is critical for maintaining genomic integrity in the face of endogenous and exogenous DNA damage, including oxidation, deamination, and alkylation [3,6]. The reaction cleaves the N-C1' glycosidic bond between the target base and the deoxyribose sugar, releasing a free base and generating an apurinic/apyrimidinic (AP) site that is further processed by downstream BER enzymes. Researchers study DNA N-glycosylases to understand mechanisms of mutagenesis, cancer predisposition, and resistance to DNA-damaging therapies such as temozolomide. The diversity of DNA N-glycosylases, including uracil-DNA glycosylases (UNG, SMUG1), alkylpurine glycosylases (MPG), and oxidized base-specific enzymes (OGG1, NTHL1, NEIL1-3), reflects the wide range of lesions that must be repaired to prevent mutations and cell death [5,6,7,8]. This article provides a comprehensive overview of GO:0019104, covering its definition, biological significance, key genes, regulatory mechanisms, disease associations, and experimental models for research. It is intended for molecular biologists, cancer researchers, and drug discovery scientists seeking to manipulate DNA N-glycosylase activity for therapeutic benefit.
DNA N-glycosylase activity At A Glance
| GO ID | GO:0019104 |
|---|---|
| GO term | DNA N-glycosylase activity |
| Ontology | molecular_function |
| Synonym | DNA glycosylase activity, endonuclease VIII activity |
| Definition | Catalysis of the removal of damaged bases by cleaving the N-C1' glycosidic bond between the target damaged DNA base and the deoxyribose sugar. The reaction releases a free base and leaves an apurinic/apyrimidinic (AP) site. |
| Major function | Initiates base excision repair by removing damaged or mismatched bases from DNA. |
| EC number | 3.2.2.- |
| Related pathways | Base excision repair (BER), DNA damage response. |
What Is GO:0019104?
DNA N-glycosylase activity (GO:0019104) is defined as the catalysis of the removal of damaged bases by cleaving the N-C1' glycosidic bond between the target damaged DNA base and the deoxyribose sugar. This reaction releases a free base and leaves an apurinic/apyrimidinic (AP) site, which is subsequently processed by AP endonucleases and other BER factors.
Why Is DNA N-glycosylase activity Important in Cell Biology?
DNA N-glycosylase activity is essential for genome maintenance and cell survival, as it initiates the repair of a wide spectrum of DNA lesions that would otherwise lead to mutations, replication fork collapse, and cell death. Deficiencies in specific DNA N-glycosylases are associated with human diseases, including cancer predisposition (e.g., MUTYH-associated polyposis, NTHL1-associated tumor syndrome) and neurological disorders [3,7]. Moreover, DNA N-glycosylase activity modulates the efficacy of alkylating chemotherapies such as temozolomide, making it a target for overcoming drug resistance in glioblastoma and other cancers.
• Maintains genomic stability by removing oxidized, deaminated, and alkylated bases.
• Prevents mutations that can drive cancer initiation and progression.
• Determines sensitivity to DNA-damaging chemotherapeutics like temozolomide.
• Plays a role in epigenetic regulation by removing 5-methylcytosine oxidation products.
• Defects in NTHL1 cause a multi-tumor predisposition syndrome.
• SMUG1 and UNG are involved in antibody diversification and class-switch recombination.
• MPG (methylpurine DNA glycosylase) processes alkylation damage and influences chemotherapy response.
• NEIL1 and NEIL2 are involved in repair of oxidized bases in transcribed genes.
• MUTYH prevents mutations caused by oxidative damage to guanine.
• DNA N-glycosylases are potential targets for cancer therapy and chemoprevention.
Molecular Mechanism of DNA N-glycosylase activity
Substrate Recognition and Base Flipping
In simple terms: The enzyme finds a damaged base and flips it out of the DNA helix to check it.
DNA N-glycosylases scan DNA for abnormal bases by flipping the target nucleotide out of the double helix and into the enzyme's active site. This base-flipping mechanism allows the enzyme to discriminate between normal and damaged bases through specific hydrogen-bonding and steric interactions. For example, uracil-DNA N-glycosylase (UNG) from Deinococcus radiodurans uses a conserved motif to recognize uracil and flip it into the catalytic pocket. Human methylpurine DNA N-glycosylase (MPG) exhibits broad substrate specificity for alkylated purines, including N7-methylguanine and N3-methyladenine, and uses a similar base-flipping strategy.
Catalysis of Glycosidic Bond Cleavage
In simple terms: The enzyme cuts the bond between the damaged base and the sugar, releasing the base.
Once the damaged base is flipped into the active site, the enzyme cleaves the N-C1' glycosidic bond. This reaction is typically catalyzed by an activated water molecule or an amino acid residue acting as a nucleophile, generating a free base and an AP site. The catalytic mechanism varies among DNA N-glycosylases; for instance, uracil-DNA glycosylases use a conserved aspartate residue to stabilize the transition state, while endonuclease VIII-like enzymes (NEIL1-3) employ a different catalytic strategy involving a proline residue.
AP Site Formation and Handoff to BER
In simple terms: After the base is removed, the enzyme leaves a gap that other repair proteins recognize.
The product of DNA N-glycosylase activity is an AP site, which is a cytotoxic and mutagenic intermediate. AP sites are recognized by AP endonuclease 1 (APE1) in humans, which incises the DNA backbone to initiate the next steps of base excision repair. Some DNA N-glycosylases, such as NEIL1 and NEIL2, possess intrinsic AP lyase activity and can directly cleave the AP site via beta-elimination, generating a single-strand break with a 3'-phosphate or 3'-phospho-alpha,beta-unsaturated aldehyde.
Substrate Specificity and Redundancy
In simple terms: Different enzymes specialize in different types of damage, but they can back each other up.
Mammalian cells express multiple DNA N-glycosylases with overlapping substrate specificities, ensuring robust repair of diverse lesions. For example, UNG and SMUG1 both remove uracil from DNA, but SMUG1 also excises 5-hydroxymethyluracil and other oxidized pyrimidines [5,8]. Similarly, OGG1, NTHL1, and NEIL1-3 collectively repair oxidized purines and pyrimidines. This redundancy complicates genetic studies, as single gene knockouts may not produce overt phenotypes due to compensation by other glycosylases.
Regulation and Post-Translational Modifications
In simple terms: The activity of these enzymes can be turned up or down by chemical modifications.
DNA N-glycosylase activity is regulated at multiple levels, including transcriptional induction, alternative splicing, and post-translational modifications. For instance, NTHL1 undergoes alternative splicing to produce multiple mRNA transcripts with potentially distinct functions. Phosphorylation, acetylation, and ubiquitination of DNA N-glycosylases can affect their stability, subcellular localization, and catalytic activity. Additionally, protein-protein interactions with other BER factors, such as XRCC1 and APE1, coordinate the repair process.
Key Genes Involved in GO:0019104 DNA N-glycosylase activity
The following table lists key genes encoding DNA N-glycosylases and their major roles in DNA repair and disease.
| Gene | Major Role | Research Relevance |
|---|---|---|
| UNG | Uracil-DNA glycosylase; removes uracil from DNA | Studied for roles in antibody diversification, HIV restriction, and cancer [5,8] |
| SMUG1 | Single-strand selective monofunctional uracil-DNA glycosylase; removes uracil and oxidized pyrimidines | Identified as the major 5-hydroxymethyluracil DNA N-glycosylase in mammals |
| MBD4 | Methyl-CpG-binding domain protein 4; removes thymine from G:T mismatches | Involved in epigenetic regulation and cancer |
| TDG | Thymine-DNA glycosylase; removes thymine and uracil from G:T/G:U mismatches | Plays a role in active DNA demethylation |
| OGG1 | 8-oxoguanine DNA glycosylase; removes 8-oxo-7,8-dihydroguanine | Associated with cancer risk and neurodegeneration |
| NTHL1 | Endonuclease III-like 1; removes oxidized pyrimidines | Biallelic mutations cause NTHL1-associated tumor syndrome |
| NEIL1 | Nei-like 1; removes oxidized pyrimidines and imidazole ring-opened purines | Involved in repair of oxidative damage in transcribed genes |
| NEIL2 | Nei-like 2; removes oxidized bases from single-stranded DNA | Plays a role in transcription-coupled repair |
| NEIL3 | Nei-like 3; removes oxidized bases from single-stranded DNA | Implicated in replication-associated repair |
| MPG | Methylpurine DNA glycosylase; removes alkylated purines | Determines sensitivity to alkylating agents |
| MUTYH | MutY homolog; removes adenine mispaired with 8-oxoguanine | Biallelic mutations cause MUTYH-associated polyposis |
| APEX1 | AP endonuclease 1; not a glycosylase but processes AP sites | Essential for BER downstream of glycosylases |
| XRCC1 | X-ray repair cross-complementing protein 1; scaffold in BER | Coordinates BER complex assembly |
| POLB | DNA polymerase beta; fills gaps in BER | Important for BER completion |
| LIG3 | DNA ligase III; seals nicks in BER | Works with XRCC1 in BER |
| PARP1 | Poly(ADP-ribose) polymerase 1; detects DNA breaks | Involved in BER and synthetic lethality with glycosylase defects |
| FEN1 | Flap endonuclease 1; processes BER intermediates | Participates in long-patch BER |
| PCNA | Proliferating cell nuclear antigen; processivity factor | Coordinates BER and replication |
How Is DNA N-glycosylase activity Regulated?
DNA N-glycosylase activity is regulated at multiple levels. Transcriptional regulation occurs in response to DNA damage, with some genes induced by p53 or other stress-responsive transcription factors. Alternative splicing generates multiple isoforms, as shown for NTHL1, which produces several mRNA transcripts with potentially different functions. Post-translational modifications, including phosphorylation, acetylation, and ubiquitination, modulate enzyme stability, localization, and activity. Protein-protein interactions within the BER complex, such as those mediated by XRCC1, ensure efficient handoff of repair intermediates. Additionally, the cellular redox state can influence the activity of DNA N-glycosylases, particularly those involved in oxidative damage repair.
DNA N-glycosylase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MUTYH | MUTYH-associated polyposis, colorectal cancer | Knockout mouse, patient-derived organoids |
| NTHL1 | NTHL1-associated tumor syndrome | Knockout cell lines, conditional knockout mice |
| OGG1 | Cancer risk, neurodegeneration | Knockout mice, neuronal cell models |
| MPG | Temozolomide resistance in glioblastoma | Overexpression and knockout glioma cell lines |
| SMUG1 | Cancer, immune dysfunction | Knockout mice, B-cell models |
Cancer Predisposition and Progression
Defects in DNA N-glycosylases are associated with increased cancer risk. Biallelic mutations in MUTYH cause MUTYH-associated polyposis, characterized by multiple colorectal adenomas and increased colorectal cancer risk. Similarly, biallelic mutations in NTHL1 cause a multi-tumor predisposition syndrome with colorectal cancer, breast cancer, and other malignancies. OGG1 and NEIL1 variants have been linked to increased risk of lung, prostate, and other cancers. In addition, DNA N-glycosylase activity can influence tumor response to chemotherapy; for example, high expression of MPG (methylpurine DNA glycosylase) contributes to temozolomide resistance in glioblastoma multiforme.
Neurodegeneration
Oxidative DNA damage accumulates in neurons due to high metabolic activity and limited repair capacity. Deficiencies in OGG1 and NEIL1 have been implicated in neurodegenerative diseases such as Alzheimer's disease and amyotrophic lateral sclerosis. The accumulation of 8-oxoguanine in mitochondrial DNA, repaired by OGG1, is thought to contribute to neuronal dysfunction.
Chemotherapy Resistance
DNA N-glycosylase activity modulates the cytotoxicity of alkylating agents and other DNA-damaging drugs. Temozolomide, a standard treatment for glioblastoma, induces O6-methylguanine and N7-methylguanine lesions; MPG removes N7-methylguanine, and its activity can influence drug sensitivity [1,6]. Overexpression of MPG has been associated with temozolomide resistance, making it a potential therapeutic target.
From DNA N-glycosylase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a DNA N-glycosylase increase mutation rate? | CRISPR knockout cell lines (e.g., HAP1, HEK293T) followed by whole-genome sequencing |
| Does a specific point mutation in a glycosylase affect substrate specificity? | CRISPR point mutation knock-in cell lines |
| Does overexpression of MPG confer temozolomide resistance? | Overexpression cell lines (e.g., U87, T98G) treated with temozolomide |
| Does a glycosylase interact with other BER proteins? | Endogenous tagged knock-in (e.g., GFP, HA) followed by immunoprecipitation |
| Does a glycosylase deficiency alter sensitivity to PARP inhibitors? | CRISPR knockout in cancer cell lines and drug sensitivity assays |
| Does a glycosylase variant affect DNA repair capacity? | Knock-in of patient-derived mutations in isogenic cell lines |
How to Study the DNA N-glycosylase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| In vitro glycosylase assay | Enzyme activity on defined substrates | Substrate specificity and kinetics [6,8] |
| CRISPR knockout screening | Gene essentiality and drug sensitivity | Identifying synthetic lethal interactions |
| RNA-seq | Gene expression and splicing | Quantifying glycosylase isoforms |
| Proteomics | Protein abundance and modifications | Detecting post-translational modifications |
| Immunofluorescence | Subcellular localization and foci formation | Visualizing repair dynamics |
| Comet assay | DNA strand breaks | Measuring overall DNA damage and repair |
| Mass spectrometry | DNA adducts and repair intermediates | Quantifying lesion removal |
| Next-generation sequencing | Mutation signatures | Assessing genome instability |
Measuring DNA N-glycosylase Activity In Vitro
In vitro assays using defined oligonucleotide substrates containing specific lesions (e.g., uracil, 8-oxoguanine, methylated bases) are used to measure glycosylase activity. The substrate is incubated with cell extracts or purified enzyme, and the cleavage product (AP site) is detected by gel electrophoresis, mass spectrometry, or fluorescent probes [6,8]. These assays allow determination of substrate specificity and kinetic parameters.
CRISPR Screening for DNA Repair Genes
Genome-wide CRISPR knockout screens can identify genes that modulate sensitivity to DNA-damaging agents. Libraries targeting DNA repair genes, including all DNA N-glycosylases, are used to discover synthetic lethal interactions and resistance mechanisms. Such screens have revealed that loss of specific glycosylases can sensitize cancer cells to certain chemotherapies.
Transcriptomic and Proteomic Profiling
RNA-seq and proteomics can quantify expression levels of DNA N-glycosylases and their isoforms. For example, targeted DNA-seq and RNA-seq have been used to identify novel NTHL1 transcripts. Proteomic approaches can detect post-translational modifications and interaction partners of DNA N-glycosylases.
Imaging DNA Repair Foci
Fluorescence microscopy can visualize the recruitment of DNA N-glycosylases and downstream BER factors to sites of DNA damage. GFP-tagged glycosylases or antibodies against endogenous proteins are used to monitor foci formation after laser microirradiation or treatment with DNA-damaging agents. This provides spatial and temporal information about repair dynamics.
How CRISPR Can Be Used to Study GO:0019104 DNA N-glycosylase activity
Knockout
CRISPR knockout of DNA N-glycosylase genes (e.g., UNG, OGG1, MUTYH) in cell lines or animal models allows researchers to study loss-of-function phenotypes, including increased mutation rates, sensitivity to DNA-damaging agents, and synthetic lethality with other repair defects. Knockout models are essential for dissecting the contribution of individual glycosylases to BER.
Point Mutation
CRISPR point mutation knock-in can introduce specific amino acid substitutions identified in patient tumors or functional studies. For example, catalytic residues or DNA-binding motifs can be mutated to abrogate activity without affecting protein stability, enabling precise structure-function analysis [4,6]. Point mutations can also model disease-associated variants.
Knock-in
Knock-in of epitope tags (e.g., GFP, HA) or fluorescent proteins at endogenous loci allows for real-time imaging and immunoprecipitation of DNA N-glycosylases under native expression conditions. Knock-in of patient-derived mutations or alternative splice isoforms can model disease mechanisms.
Overexpression
Overexpression of DNA N-glycosylases (e.g., MPG, OGG1) via lentiviral or CRISPR activation systems can model chemoresistance and identify downstream effects on DNA repair capacity and cell survival. Overexpression studies complement knockout approaches by revealing gain-of-function phenotypes.
How EDITGENE Supports DNA N-glycosylase activity Research
Researchers studying DNA N-glycosylase activity-related genes often need to determine whether a candidate gene is causally involved in DNA repair, disease predisposition, or drug response. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell and animal models, enabling functional validation of DNA N-glycosylases and their variants.
Contact EDITGENE today to design your custom CRISPR model for DNA N-glycosylase activity research.
Frequently Asked Questions About DNA N-glycosylase activity
What is DNA N-glycosylase activity?
DNA N-glycosylase activity (GO:0019104) is a molecular function that removes damaged or mismatched bases from DNA by cleaving the N-C1' glycosidic bond, leaving an apurinic/apyrimidinic (AP) site.
What genes are involved in DNA N-glycosylase activity?
Key genes include UNG, SMUG1, MBD4, TDG, OGG1, NTHL1, NEIL1, NEIL2, NEIL3, MPG, and MUTYH, each encoding enzymes with distinct substrate specificities [3,5,6,7,8].
What is the role of DNA N-glycosylase in base excision repair?
DNA N-glycosylases initiate base excision repair by removing damaged bases, creating an AP site that is further processed by AP endonucleases and other BER factors.
How is DNA N-glycosylase activity measured?
Activity is measured using in vitro assays with defined oligonucleotide substrates containing specific lesions, followed by detection of cleavage products by gel electrophoresis or mass spectrometry [6,8].
What diseases are associated with DNA N-glycosylase defects?
Defects are linked to cancer predisposition (e.g., MUTYH-associated polyposis, NTHL1-associated tumor syndrome), neurodegeneration, and chemotherapy resistance [1,3,7].
What is the difference between UNG and SMUG1?
UNG primarily removes uracil from DNA, while SMUG1 removes uracil and oxidized pyrimidines such as 5-hydroxymethyluracil, and is the major 5-hydroxymethyluracil DNA N-glycosylase in mammals [5,8].
How does MPG contribute to temozolomide resistance?
MPG removes N7-methylguanine and N3-methyladenine induced by temozolomide; high MPG activity can enhance repair and contribute to resistance in glioblastoma [1,6].
Can CRISPR be used to study DNA N-glycosylase function?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable precise dissection of DNA N-glycosylase function in DNA repair, disease, and drug response [3,7].
What is the substrate specificity of human methylpurine DNA N-glycosylase?
Human MPG recognizes and removes a broad range of alkylated purines, including N7-methylguanine, N3-methyladenine, and N7-methylhypoxanthine.
What are the synonyms for DNA N-glycosylase activity?
Synonyms include DNA glycosylase activity and endonuclease VIII activity.
Conclusion
DNA N-glycosylase activity (GO:0019104) is a cornerstone of genome maintenance, initiating base excision repair to remove damaged bases and prevent mutations. The diversity of DNA N-glycosylases and their overlapping substrate specificities ensure robust repair, but also complicate genetic studies. Defects in these enzymes are linked to cancer, neurodegeneration, and chemotherapy resistance, making them attractive targets for therapeutic intervention. Advanced CRISPR models and screening technologies are essential for dissecting their roles and developing new treatments.
References
- 1. Lee SY. 2016. Temozolomide resistance in glioblastoma multiforme.. Genes Dis 3(3):198-210 PMID: 30258889
- 3. Parsons JL et al.. 2003. DNA N-glycosylase deficient mice: a tale of redundancy.. Mutat Res 531(1-2):165-75 PMID: 14637253
- 4. Pedersen HL et al.. 2015. Structure determination of uracil-DNA N-glycosylase from Deinococcus radiodurans in complex with DNA.. Acta Crystallogr D Biol Crystallogr 71(Pt 10):2137-49 PMID: 26457437
- 5. Boorstein RJ et al.. 2001. Definitive identification of mammalian 5-hydroxymethyluracil DNA N-glycosylase activity as SMUG1.. J Biol Chem 276(45):41991-7 PMID: 11526119
- 6. Asaeda A et al.. 2000. Substrate specificity of human methylpurine DNA N-glycosylase.. Biochemistry 39(8):1959-65 PMID: 10684645
- 7. Diamantopoulos MA et al.. 2024. Unraveling novel mRNA transcripts of the human DNA N-glycosylase 1 (NTHL1) gene with the implementation of an innovative targeted DNA-seq assay.. Gene 930:148856 PMID: 39147115
- 8. Dizdaroglu M et al.. 1996. Novel activities of human uracil DNA N-glycosylase for cytosine-derived products of oxidative DNA damage.. Nucleic Acids Res 24(3):418-22 PMID: 8602352
